
News|Videos|November 20, 2026
Executive Conversations: How Patient Advocacy Is Shaping Channel Design
In Episode 2, Part 4, Cheryl Allen, Nick Calla and Rena Goins discuss how the industry is building channels around complex products.
Advertisement
Advertisement
The second episode of Executive Conversations: The Future of Pharmaceutical Commercialization concludes by asking what the industry is doing differently as it builds channels around complex products. Curatio Advisors partner Cheryl Allen leads the discussion with Nick Calla, senior vice president of industry relations at Orsini Specialty Pharmacy, and Rena Goins, executive director of commercial trade and distribution at Regeneron Pharmaceuticals.
Related to this article

In Episode 2, Part 3, Cheryl Allen, Nick Calla and Rena Goins discuss where manufacturers should start when evaluating the channel.

In Episode 2, Part 2, Cheryl Allen, Nick Calla and Rena Goins discuss where traditional channel models break down as therapies grow more complex.

In Episode 2, Part 1, Cheryl Allen, Nick Calla and Rena Goins discuss whether today's channel models are ready for an increasingly complex pipeline.

Asembia's Ray Tancredi explains why manufacturer and specialty pharmacy trade talks now center on getting patients on therapy.

In Episode 1, Part 4, Jon Hamrick, Rena Goins and Bob Cochran explain what separates trade teams seen as strategic partners from those that aren't.

In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.

In Episode 1, Part 2, Jon Hamrick, Bob Cochran and Rena Goins explain why trade belongs in commercial planning at least a year before launch.
Advertisement
Advertisement

